Nanomedicines Alliance Session at 2nd FDA/PQRI Conference on Advancing Product Quality
On 5 October 2015, the Nanomedicines Alliance will co-lead the panel session Current Challenges in the Characterization of Complex Drug Formulations Containing Nanomaterials with FDA at the 2nd FDA/PQRI Conference on Advancing Product Quality in Bethesda, MD.
Nanomedicines: Charting a Roadmap to Commercialization
On 6-7 March 2013, the Nanomedicines Alliance held an Industry Symposium: Charting a Road to Commercialization. A white paper on the Symposium, Nanomedicine Drug Development: A Scientific Symposium Entitled Charting a Roadmap to Commercialization, has been published in the AAPS Journal.
The Symposium addressed:
- desigining nanomedicines
- preclinical pharmacology
- chemistry, manufacturing & controls
- toxicology/ADME and
- clinical studies